NOXXON: Targeting the Chemokines of the TME to enhance Cancer Therapies

From a doctorate at the SALK Institute overlooking La Jolla Cove, to an MBA from INSEAD, the world-leading business school located near Paris, NOXXON CEO Aram Mangasarian knows his way around different environments. Now he’s focused on tackling the tumor micro-environment (TME) and targeting the chemokines that drive tumor immunosuppression. Lead asset, NOX-A12, has generated exciting early results in some of the most challenging tumor types: pancreatic cancer and glioblastoma.